Hematological malignancies
Conditions
Interventions
case series:none
Sponsors
The First Affiliated Hospital of Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
8 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The subjects or their legal representatives signed the informed consent before the clinical study. 2. Subjects aged 8 to 65 years. 3. Patients have no suitable HLA identical sibling donor. 4. Patients with malignant hematological diseases plan to receive peripheral blood stem cell donor source T cell replete haoloidentical stem cell transplantation. 5. Patients with ECoG score of 0-2. 6. Patients who received myeloablative conditioning regimen treatment. 7. Accepting anti-T-lymphocyte globin(ATG) based GVHD prophylaxis.
Exclusion criteria
Exclusion criteria: 1. Patients have suitable HLA identical sibling donor. 2. Patients with severe liver and kidney function (alanine aminotransferase > 2.5 times of the upper normal limit, serum creatinine > 1.5 times of the upper normal limit), cardiopulmonary dysfunction (cardiac function NYHA III / IV, cardiac ejection fraction < 50%, severe obstructive or restrictive ventilation dysfunction). 3. Patients with active infection. 4. Patients diagnosed with aplastic anemia before transplantation. 5. Patients with secondary tumor. 6. Patients who received reduced-intensity conditioning treatment. 7. Patients who received a second transplant. 8. Patients who cannot independently choose to enter or exit clinical trials due to serious central nervous system disease or mental disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;incidence of graft versus host disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| non-relapses mortality;disease-free survival;incidence of relapse; | — |
Countries
China
Contacts
Public ContactHuang He
The First Affiliated Hospital of Medical College of Zhejiang University
Outcome results
None listed